June 2024 Insight Into Three Swedish Stocks Trading Below Estimated Value

In This Article:

As global markets exhibit mixed signals with some regions showing growth while others face economic slowdowns, the Swedish stock market presents unique opportunities for investors looking for value. In such a landscape, identifying stocks that trade below their estimated intrinsic values could offer potential for substantial returns.

Top 10 Undervalued Stocks Based On Cash Flows In Sweden

Name

Current Price

Fair Value (Est)

Discount (Est)

Bj?rn Borg (OM:BORG)

SEK54.90

SEK102.16

46.3%

Arcoma (OM:ARCOMA)

SEK18.00

SEK35.84

49.8%

Boule Diagnostics (OM:BOUL)

SEK10.60

SEK21.00

49.5%

Biotage (OM:BIOT)

SEK155.80

SEK297.39

47.6%

Nordic Waterproofing Holding (OM:NWG)

SEK161.00

SEK296.94

45.8%

Net Insight (OM:NETI B)

SEK4.93

SEK9.85

50%

Nolato (OM:NOLA B)

SEK56.95

SEK111.50

48.9%

MilDef Group (OM:MILDEF)

SEK69.60

SEK132.41

47.4%

Humble Group (OM:HUMBLE)

SEK10.42

SEK19.62

46.9%

Gigasun (OM:GIGA)

SEK3.85

SEK7.51

48.7%

Click here to see the full list of 48 stocks from our Undervalued Swedish Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results

Biotage

Overview: Biotage AB (publ) specializes in providing solutions and products for drug discovery and development, analytical testing, as well as water and environmental testing, with a market capitalization of SEK 12.47 billion.

Operations: The company generates SEK 1.98 billion in revenue from its healthcare software segment.

Estimated Discount To Fair Value: 47.6%

Biotage, priced at SEK 155.8, is significantly undervalued based on a DCF valuation of SEK 297.39, trading 47.6% below its estimated fair value. Despite a recent dip in net income and EPS as reported in Q1 2024 results, Biotage's earnings are expected to grow by approximately 20% annually over the next three years, outpacing the Swedish market's average. Revenue growth projections also exceed market trends at an annual rate of 11.2%, highlighting potential for appreciation despite current financial inconsistencies.

OM:BIOT Discounted Cash Flow as at Jun 2024
OM:BIOT Discounted Cash Flow as at Jun 2024

Nolato

Overview: Nolato AB specializes in developing, manufacturing, and selling plastic, silicone, and thermoplastic elastomer products across various sectors including medical technology, pharmaceuticals, consumer electronics, and automotive. The company operates globally with a market capitalization of SEK 15.34 billion.

Operations: The revenue for the Medical Solutions segment is SEK 5.34 billion.

Estimated Discount To Fair Value: 48.9%